Korro Bio (KRRO) Director Formela Jean Francois Sells 2,143 Shares

What Happened
Formela Jean Francois, a director of Korro Bio (KRRO), sold a total of 2,143 shares in open-market transactions on August 11, 2026. The shares were sold at a weighted average price of $13.96 (range $13.95–$14.00), producing aggregate proceeds of approximately $29,916. These sales were made pursuant to a Rule 10b5-1 trading plan adopted April 8, 2026.

Key Details

• Transaction date: 2026-08-11 (filed with SEC on 2026-08-13 — timely filing).
• Sales: 1,775 shares @ $13.96 (≈ $24,779) and 368 shares @ $13.96 (≈ $5,137); total 2,143 shares for ≈ $29,916.
• Reported price: Weighted average $13.96; actual trade prices ranged $13.95–$14.00 (reporting person can provide per-price breakdown on request).
• Shares owned after transaction: Not specified in the provided filing excerpt; filing notes the shares sold are held directly by Atlas Venture funds and the reporting person disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.
• Notable footnotes: Sales made under a pre-arranged Rule 10b5-1 plan; the shares sold are held by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., with the reporting person positioned in the funds’ GP/manager structure and disclaiming beneficial ownership.

Context
This was a sale executed under a 10b5-1 plan, which is a pre-established trading arrangement and is commonly used by insiders to sell shares according to preset rules. The filing indicates institutional fund ownership (Atlas Venture funds) and a disclaimer of direct Section 16 beneficial ownership by the reporting person, so these transactions reflect disposals of fund-held shares rather than clear personal trading decisions by an executive.